Fujirebio Launches Neurodegeneration Assay for Automated Blood-Based Alzheimer’s Disease Biomarker Testing
|
By LabMedica International staff writers Posted on 02 Mar 2022 |
|
Fujirebio (Gent, Belgium) has entered the field of fully automated blood-based Alzheimer’s disease (AD) biomarker testing with the release of the Lumipulse G pTau 181 Plasma assay for research use only.
Fujirebio has announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of Tau phosphorylated at threonine 181 in human plasma within just 35 minutes. With the launch of this new neurodegeneration assay, automated blood-based biomarker testing for AD, and testing for plasma pTau 181 in particular, may soon transition from research to clinical routine. The assay is available for research use only and will allow researchers and clinical research professionals to further study the clinical utility of this marker on the Lumipulse platform that has the required throughput and meets the regulatory requirements to support possible future routine use.
The Lumipulse G pTau 181 Plasma assay complements the panel of four key cerebrospinal fluid (CSF) assays (Aβ1-42, Aβ1-40, tTau and pTau 181) already available on the LUMIPULSE G platform. These four CSF parameters can provide essential information on the presence of amyloid and tau pathology in neurodegenerative disease. There is hope that blood-based testing can become an even simpler, more accessible, and more scalable approach to help support the diagnosis of AD. The plasma pTau 181 marker also has the potential to further advance the development of disease-modifying treatments by streamlining patient eligibility for clinical trials and monitoring of patients on such future treatments
“The projected increase in the number of people suffering from dementia1 poses significant public health challenges worldwide, of which early diagnosis will be of particular importance,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Fujirebio is rising to this challenge with the availability of a fully automated plasma pTau 181 assay on our well recognized LUMIPULSE G platform. This breakthrough opens another new chapter in the field of neurodegeneration testing.”
Related Links:
Fujirebio
Latest Hematology News
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Channels
Clinical Chemistry
view channel
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more
New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
Stroke affects more than 795,000 Americans each year, leaving many survivors with lasting motor, speech, and cognitive deficits. Because rehabilitation outcomes vary widely, clinicians still face challenges... Read more
NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies... Read more
Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
Lung cancer is often diagnosed at advanced stages because symptoms typically appear late, while participation in low-dose computed tomography (LDCT) screening remains low. Imaging can also produce false-positive... Read moreMolecular Diagnostics
view channel
Urine Genomic Test Detects More Than Nine in Ten Suspected Bladder Cancers
Urgent evaluation for suspected bladder cancer often sends patients to cystoscopy, an invasive and resource-intensive procedure, even though relatively few ultimately have cancer. This places pressure... Read more
Liquid Biopsy Test Predicts Tissue of Origin in Cancer of Unknown Primary
Cancers of unknown primary and other uncertain tumor presentations can complicate therapy selection, especially in community oncology settings where subspecialty pathology resources may be limited.... Read more
Immunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more
Microbiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Pathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Industry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more
